Search All Tech Briefings


Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available.  Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 1173 Results

Title
Intervention Indication Therapeutic Area Year Actions
Apadamtase alfa for treating acute thrombotic thrombocytopenic purpura (TTP) episodes associated with congenital TTP (cTTP) and long-term prophylaxis in patients with congenital ADAMTS-13 deficiency Apadamtase alfa congenital ADAMTS-13 deficiency , Thrombotic thrombocytopenic purpura Haematology 2022 View  |  Download
Apabetalone in addition to high-intensity statin therapy for preventing major adverse cardiac events in high-risk cardiovascular disease patients with type 2 diabetes mellitus Apabetalone (RVX-208) Major adverse cardiovascular events (MACE) Cardiovascular System , Endocrine Nutritional and Metabolic Disorders 2018 View  |  Download
Anifrolumab for moderately to severly active, autoantibody-positive systemic lupus erythematosus Anifrolumab (MEDI546) Systemic lupus erythematosus (SLE) Immunology , Nephrology 2020 View  |  Download
Angiotensin II acetate (Giapreza) for vasopressor resistant hypotension due to distributive shock Angiotensin II acetate (Giapreza; LJPC-501) Orthostatic hypotension Cardiovascular System 2018 View  |  Download
Anakinra for Still’s disease Anakinra (Kineret) Juvenile idiopathic arthritis Rheumatology 2018 View  |  Download
Amivantamab with lazertinib for previously untreated locally advanced or metastatic non-small-cell lung cancer Amivantamab (JNJ-6372; JNJ-61186372) , Lazertinib Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2023 View  |  Download
Amivantamab with chemotherapy for previously untreated advanced EGFR exon 20 insertion mutations positive non-small cell lung cancer Amivantamab (JNJ-6372; JNJ-61186372) , Chemotherapy Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2022 View  |  Download
Amivantamab for advanced non-small-cell lung cancer Amivantamab (JNJ-6372; JNJ-61186372) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2021 View  |  Download
AMG 510 for KRAS G12c mutated metastatic non-small cell lung cancer - after prior standard therapy Sotorasib (AMG 510) Non-small-cell lung cancer (NSCLC) Lung and Respiratory Cancer 2020 View  |  Download
ALXN 1210 for Paroxysmal Nocturnal Haemoglobinuria – First Line Ravulizumab (ALXN1210; Ultomiris) Paroxysmal nocturnal haemoglobinuria (PNH) Haematology 2017 View  |  Download
Medicines
Medicine Industry's Gateway to NICE
Support for Industry
Outputs & Publications